Piet L. van Riel

538 total citations
13 papers, 404 citations indexed

About

Piet L. van Riel is a scholar working on Rheumatology, Immunology and Oncology. According to data from OpenAlex, Piet L. van Riel has authored 13 papers receiving a total of 404 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Rheumatology, 4 papers in Immunology and 3 papers in Oncology. Recurrent topics in Piet L. van Riel's work include Rheumatoid Arthritis Research and Therapies (7 papers), Systemic Lupus Erythematosus Research (3 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Piet L. van Riel is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (7 papers), Systemic Lupus Erythematosus Research (3 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Piet L. van Riel collaborates with scholars based in Netherlands, United States and Brazil. Piet L. van Riel's co-authors include Wietske Kievit, Mihai G. Netea, Alfons A den Broeder, Leo A. B. Joosten, Jaap Fransen, Bas Heinhuis, Charles A. Dinarello, Aatke van der Maas, Bart J. F. van den Bemt and F.H.J. van den Hoogen and has published in prestigious journals such as Scientific Reports, Annals of the Rheumatic Diseases and Patient Education and Counseling.

In The Last Decade

Piet L. van Riel

13 papers receiving 398 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Piet L. van Riel Netherlands 11 209 146 81 73 58 13 404
Masahiro Yokosawa Japan 13 186 0.9× 170 1.2× 95 1.2× 64 0.9× 42 0.7× 38 443
Krishan Thirunavukkarasu Australia 7 292 1.4× 121 0.8× 142 1.8× 78 1.1× 42 0.7× 9 430
Anastas Batalov Bulgaria 12 212 1.0× 135 0.9× 69 0.9× 55 0.8× 97 1.7× 77 484
Georgina Salvador Spain 13 348 1.7× 109 0.7× 140 1.7× 33 0.5× 38 0.7× 20 501
Riitta Koivuniemi Finland 14 260 1.2× 110 0.8× 74 0.9× 58 0.8× 45 0.8× 26 496
Nicole L Byers United States 5 167 0.8× 90 0.6× 75 0.9× 91 1.2× 37 0.6× 5 377
Yvonne Sundström Sweden 10 161 0.8× 260 1.8× 30 0.4× 74 1.0× 33 0.6× 13 397
Nashla Barroso United States 4 107 0.5× 109 0.7× 48 0.6× 28 0.4× 61 1.1× 7 324
Arianna Damiani Italy 13 251 1.2× 180 1.2× 56 0.7× 86 1.2× 68 1.2× 55 633
Michelle E A Borm Netherlands 11 127 0.6× 109 0.7× 57 0.7× 138 1.9× 32 0.6× 25 459

Countries citing papers authored by Piet L. van Riel

Since Specialization
Citations

This map shows the geographic impact of Piet L. van Riel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Piet L. van Riel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Piet L. van Riel more than expected).

Fields of papers citing papers by Piet L. van Riel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Piet L. van Riel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Piet L. van Riel. The network helps show where Piet L. van Riel may publish in the future.

Co-authorship network of co-authors of Piet L. van Riel

This figure shows the co-authorship network connecting the top 25 collaborators of Piet L. van Riel. A scholar is included among the top collaborators of Piet L. van Riel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Piet L. van Riel. Piet L. van Riel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Teerenstra, Steven, Glyn Elwyn, M A van de Laar, et al.. (2021). Patient involvement in rheumatoid arthritis care to improve disease activity-based management in daily practice: A randomized controlled trial. Patient Education and Counseling. 105(5). 1244–1253. 6 indexed citations
2.
3.
Damen, Michelle S. M. A., Rabia Agca, Suzanne Holewijn, et al.. (2017). IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis. Scientific Reports. 7(1). 41629–41629. 25 indexed citations
4.
Fransen, Jaap, et al.. (2016). Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis. RMD Open. 2(2). e000202–e000202. 41 indexed citations
5.
Engelen, Baziel G.M. van, et al.. (2015). Increased fascial thickness of the deltoid muscle in dermatomyositis and polymyositis: An ultrasound study. Muscle & Nerve. 52(4). 534–539. 28 indexed citations
6.
7.
Maas, Aatke van der, Wietske Kievit, Bart J. F. van den Bemt, et al.. (2012). Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Annals of the Rheumatic Diseases. 71(11). 1849–1854. 85 indexed citations
8.
Wenink, Mark H., Kim C. M. Santegoets, John Butcher, et al.. (2011). Impaired dendritic cell proinflammatory cytokine production in psoriatic arthritis. Journal of Translational Medicine. 9(S2). 5 indexed citations
9.
Plantinga, Theo S., Jaap Fransen, Nozomi Takahashi, et al.. (2010). Functional consequences of DECTIN-1early stop codon polymorphism Y238X in rheumatoid arthritis. Arthritis Research & Therapy. 12(1). R26–R26. 24 indexed citations
10.
Heinhuis, Bas, Marije I. Koenders, Piet L. van Riel, et al.. (2010). Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade. Annals of the Rheumatic Diseases. 70(4). 660–667. 95 indexed citations
11.
Popa, Călin D., Mihai G. Netea, Pilar Barrera, et al.. (2005). Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy. Cytokine. 30(2). 72–77. 20 indexed citations
12.
Riel, Piet L. van, et al.. (1995). Management of Adverse Effects of Disease-Modifying Antirheumatic Drugs. Drug Safety. 13(4). 219–227. 13 indexed citations
13.
Riel, Piet L. van, et al.. (1990). Risk factors of second-line antirheumatic drugs in rheumatoid arthritis. Seminars in Arthritis and Rheumatism. 19(6). 337–352. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masahiro Yokosawa Breakdown of academic impact, for papers by Krishan Thirunavukkarasu Breakdown of academic impact, for papers by Anastas Batalov Breakdown of academic impact, for papers by Georgina Salvador Breakdown of academic impact, for papers by Riitta Koivuniemi Breakdown of academic impact, for papers by Nicole L Byers Breakdown of academic impact, for papers by Yvonne Sundström Breakdown of academic impact, for papers by Nashla Barroso Breakdown of academic impact, for papers by Arianna Damiani Breakdown of academic impact, for papers by Michelle E A Borm
Rankless by CCL
2026